Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts
Novo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Taproot Management David Lin And Jason Beverage | 0 | $0 | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,236,009 | $155,134,271 | 8.49% | |
| 2. | 504,918 | $24,205,769 | 0.34% | |
| 3. | 426,700 | $20,455,998 | 1.91% | |
| 4. | 369,120 | $17,695,613 | 1.91% | |
| 5. | 320,656 | $15,372,249 | 3.93% |